VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”). The Company will be offering 9,666,988…


Previous articleRevive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Next articleWesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery